Compare AURE & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURE | NEPH |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 39.0M |
| IPO Year | 2019 | 2004 |
| Metric | AURE | NEPH |
|---|---|---|
| Price | $1.04 | $3.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | ★ 65.9K | 41.9K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | N/A | $15.90 |
| P/E Ratio | ★ N/A | $29.63 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.18 | $2.66 |
| 52 Week High | $3.53 | $6.42 |
| Indicator | AURE | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 46.29 |
| Support Level | $1.00 | $3.15 |
| Resistance Level | $1.11 | $3.78 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 69.23 | 77.08 |
Aurelion Inc is a publicly traded company building a digital gold risk and technology infrastructure around XAUT, on-chain gold backed by physical LBMA bars. XAUT combines the stability of physical gold with the efficiency of blockchain, giving investors access to a tokenized gold reserve that could serve as a hedge against inflation, currency devaluation, and crypto volatility. In parallel with building a business around tokenized gold, Aurelion provides wealth and asset management services.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.